Question

This approved therapy for relapsing remitting MS included a warning to monitor depression because of a suicide during the phase III trial. a. Avonex b. Betaseron c. Copaxone d. Rebif

Short answer

Answer: Copaxone

Step-by-step solution

Understand the question

Carefully read the question to ensure complete understanding. In this case, the question is asking which approved therapy for relapsing-remitting MS included a warning to monitor depression because of a suicide during the phase III trial.

Identify important information

In this question, the important information is the context of relapsing-remitting MS, phase III trial, suicide and the need for the therapy to monitor depression as a warning.

Evaluate each option

Research each of the given options to determine if the important information from the question, i.e., an approved therapy for MS that included a warning to monitor depression due to a suicide during the phase III trial, applies to it. a. Avonex - Although approved for relapsing-remitting MS, there is no specific mention of a suicide during the phase III trial or a warning to monitor depression. b. Betaseron - Also approved for relapsing-remitting MS, but this therapy has no direct connection with the specific depression and suicide aspect mentioned in the question. c. Copaxone - This therapy is approved for relapsing-remitting MS and, most importantly, included a warning about monitoring depression due to a case of suicide during the phase III trial. d. Rebif - While approved for relapsing-remitting MS, this therapy does not include the specific warning tied to suicide during the phase III trial.

Select the correct answer

Based on the evaluation of the given options, the correct answer is (c) Copaxone, as it is the only therapy among the options that meets all the criteria mentioned in the question.